Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China

Journal of Medical Virology

Volumn 79, Issue 10, 2007, Pages 1593-1599

  Liu, Li ^a   Hong, Zhou Lu ^a   Henry, Mireille ^b   Tamalet, Catherine ^b  

^a Shanghai Public Health Center   (China)

^b TIMONE HOSPITAL   (France)

Author keywords

China; Drug resistance mutations; HIV 1; Natural polymorphism; Reverse transcriptase; RTI

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PRESCHOOL CHILD; TREATMENT DURATION; VIRUS RESISTANCE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHINA; FEMALE; GENES, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; SELECTION (GENETICS);

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34548259256     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20998     Document Type: Article

References (26)

1. Ceccherini-Silberstein F, Gago F, Santoro M, Gori C, Svicher V, Rodriguez-Barrios F, d'Arrigo R, Ciccozzi M, Bertoli A, d'Arminio Monforte A, Balzarini J, Antinori A, Perno CF. 2005. High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. J Virol 79:10718-10729.
2. Chaix M, Descamps D, Mouajjah S, deveau C, André P, Cottalorda J, In grand D, Izopet J, Kohli E, Masquelier B, Parmentier K, Poggi C, Rogez S, Ruffault A, Schneider V, Schmück A, Tamalet C, Wirden M, Rouzioux C, Meyer L, Brun-Vezinet F, Costagliola D, and the ANRS AC11 Resistance group, Cohort PRIMO, INTERPRIM and PRIMOSTOP study Groups. 2003. French National Sentinel Survey of antiretroviral resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. Antivir Ther 8:S137.
3. Clavel F, Hance AJ. 2004. HIV drug resistance. N Engl J Med 350:1023-1035.
4. Coakley EP, Gillis JM, Hammer SM. 2000. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 14:F9-F15.
5. Colson P, Tamalet C, Raoult D. 2006. SVARAP and aSVARAP: Simple tools for quantitative analysis of nucleotide and amino acid variability and primer selection for clinical microbiology. BMC Microbiol 6:21-28.
6. Costagliola D, Descamps D, Assoumou L, Ruffault A, Marcellin AG, Izopet J, Chaix ML, Tamalet C, Brun-Vezinet F, Masquelier B. and the ANRS AC 11 Resistance study group. 2006. Prevalence of resistance to at least one drug in treated HIV infected patients with viral load >1000 copies/ml in 2004: A French nationwide study. Abstr.6. Fourth European HIV Drug Resistance Workshop, Monte Carlo-Monaco.
7. De Luca A, Di Giambenedetto S, Romano L, Gonnelli A, Corsi P, Baldari M, Di Pietro M, Menzo S, Francisci P, Almi P, Zazzi M, and Antiretroviral Resistance Cohort Analysis Study group. 2006. Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. J Infect Dis 193:1219-1222.
8. Garcia-Lerma JG, MacInnes H, Bennett D, Reid P, Nidtha S, Weinstock H, Kaplan JE, Heneine W. 2003. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol 77:5685-5693.
9. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, Chou S, Zolopa AR, Fessel WJ, Shafer RW. 2003. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 17:791-799.
10. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. 2006. International AIDS Society-USA panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296:827-843.
11. Jiang S, Xing H, Si X, Wang Y, Shao Y. 2006. Polymorphism of the protease and reverse transcriptase and drug resistance mutation patterns of HIV-1 subtype B prevailing in China. J Acquir Immune Defic Syndr 42:512-514.
12. Kagan RM, Fenwick RF, Merigan TC. 2000. Recent trends in HIV-1 drug resistant genotypes in the patient population referred to a clinical diagnostics reference laboratory. Antivir Ther 5:125. Abstr. 158.
13. Li JY, Li HP, Li L, Li H, Wang Z, Yang K, Bao ZY, Zhuang DM, Liu SY, Liu YJ, Xing H, Shao YM. 2005. Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. Cell Res 15:843-849.
14. Little SJ, Holte S, Routy JP. 2002. Antiretroviral drug resistance among patients recently infected with HIV. N Eng J Med 347:385-394.
15. Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860.
16. Pellegrin I, Izopet J, Reynes J, Denayrolles M, Montes B, Pellegrin JL, Massip P, Puel J, Fleury H, Segondy M. 1999. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group. AIDS 13:1705-1709.
17. Roge BT, Katzenstein TL, Obel N, Nielsen H, Kirk O, Pedersen C, Mathiesen L, Lundgren J, Gerstoft J. 2003. K65R with and without S68: A new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther 8:173-182.
18. Saracino A, Monno L, Scudeller L. 2006. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors. J Med Virol 78:9-17.
19. Si XF, Huang HL, Wei M, Guan Q, Song YH, Ma PF, Quan Y, Xing H, Shao YM. 2004. Prevalence of drug resistance mutations among antiretroviral drug-naive HIV-1-infected patients in China. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 18:308-311.
20. Svicher V, Sing T, Santoro MM, Forbici F, Rodriguez-Barrios F, Bertoli A, Beerenwinkel N, Bellocchi MC, Gago F, d'Arminio Monforte A, Antinori A, Lengauer T, Ceccherini-Silberstein F, Perno CF. 2006. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 80:7186-7198.
21. Tamalet C, Fantini J, Tourres C, Yahi N. 2003. Resistance of HIV-1 to multiple antiretroviral drugs in France: A 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 17:2383-2388.
22. Wensing A, Van de Vijver DA, Asjö B. 2003. Prevalence of transmitted drug resistance in Europe is largely influenced by the presence of non-B sequences: Analysis of 1400 patients from 16 countries: The CATCH-Study. Antivir Ther 8:S131.
23. Wensing AM, van de Vijver DA, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA, SPREAD Programme. 2005. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 192:958-966.
24. Yahi N, Fantini J, Tourres C, Tivoli N, Koch N, Tamalet C. 2001. Use of drug resistance sequence data for the systematic detection of non-B human immunodeficiency virus type 1 (HIV-1) subtypes: How to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale. J Infect Dis 183:1311-1317.
25. Yahi N, Fantini J, Henry M, Tourres C, Tamalet C. 2005. Structural analysis of reverse transcriptase mutations at codon 215 explains the predominance of T215Y over T215F in HIV-1 variants selected under antiretroviral therapy. J Biomed Sci 12:701-710.
26. Zhang FJ, Pan J, Yu L, Wen Y, Zhao Y. 2005. Current progress of China's free ART program. Cell Res 15:877-882.